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12Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA
13Indiana University School of Medicine, Indianapolis, IN 46202, USA
14Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
15Leeds Teaching Hospital, Leeds, LS1 3EX, UK
16Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA
17Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA
18Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil
19M.D. Anderson Cancer Center, Houston, TX 77030, USA
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Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in
relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data
from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were
integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median
time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months.
Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy,
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33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30%
of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness
and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.
Clinical trial registration: NCT02761187 (ClinicalTrials.gov)
Lay abstract: Proteasome inhibitors are drugs used in multiple myeloma (MM), a blood cancer that devel-
ops from cells in the bone marrow. Ixazomib is the first oral proteasome inhibitor to be approved for use
in MM, when given in combination with two other oral drugs, lenalidomide and dexamethasone, to adult
patients who have received one prior therapy. Our study, which was conducted in routine clinical prac-
tice, found that the effectiveness and safety of ixazomib + lenalidomide + dexamethasone in previously
treated MM patients were similar to those seen in the Phase III clinical trial on which approval was based.
These findings are important because they suggest that MM patients in everyday practice can achieve the
same benefits from this treatment as patients in clinical trials, despite often being in poorer health.
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Outcomes in routine clinical practice (effectiveness) often differ from data reported in clinical trials (efficacy)
for multiple myeloma (MM) therapies, with poorer long-term outcomes reported for real-world patients [1,2].
Differences in patient characteristics and the strict eligibility criteria used to select patients for enrollment in
clinical trials are among the factors that may contribute to this gap. It has been reported that 40% of patients
enrolled in the CONNECT-MM registry (ClinicalTrials.gov: NCT01081028) do not meet standard eligibility
criteria for randomized trials [3]. Similarly, an analysis of over 3000 patients enrolled in the INSIGHT MM global,
prospective, observational study (NCT02761187) showed that 39% of MM patients treated in routine clinical
practice would be ineligible for trials [4]. Furthermore, a retrospective analysis of a US electronic health record
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database demonstrated that 47.9 to 72.3% of real-world patients with relapsed/refractory MM (RRMM) did not
meet the eligibility criteria for clinical trials [5]. Observational studies may therefore provide important information
on the effectiveness and safety of new therapies in routine clinical practice, as they have less stringent inclusion
criteria and consequently include a more diverse patient population that is often under-represented in clinical trials
(e.g., elderly and frail patients, patients with comorbidities and/or advanced disease and specific ethnic or racial
minorities) [3,6,7].
Differences in outcomes between real-world and clinical trial settings may also arise from variations in the
duration of therapy (DOT). Factors that can limit treatment duration in routine practice include, but are not
limited to, treatment-center effects, with academic and community centers having different levels of experience
in utilizing new regimens and managing adverse effects, and differences in patient/physician preferences for treat-
to-progression approaches. Additionally, a greater comorbidity burden compared with that in clinical trials may
affect the real-world tolerability, convenience and practicality of therapy, leading to premature discontinuation of
treatment [1]. Results from observational studies may therefore better inform the true therapeutic benefit that can
be achieved and help to guide treatment decisions in everyday practice [8].
Ixazomib, the first oral proteasome inhibitor [9], is approved in over 70 countries, in combination with
lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior
therapy [10]. Approvals were based on the results of the Phase III, double-blind TOURMALINE-MM1 study
(NCT01564537), which compared ixazomib-lenalidomide-dexamethasone (IRd) versus placebo-lenalidomide-
dexamethasone (placebo-Rd) in adults with RRMM, who had received one to three prior therapies (Supplementary
Table 1) [11]. The study demonstrated a significantly longer progression-free survival (PFS) for IRd versus placebo-
Rd (median PFS: 20.6 vs 14.7 months; hazard ratio [HR]: 0.74; 95% [CI]: 0.587–0.939; p = 0.01), as well as
significantly improved response rates (overall response rate [ORR]: 78 vs 72%; rate of very good partial response
or better [≥VGPR]: 48 vs 39%; Supplementary Table 1) [11]. Limited additional toxicity was observed in the IRd
arm compared with the placebo-Rd arm [11].
Emerging evidence from observational studies of MM patients treated with ixazomib suggests that outcomes
in routine practice may be broadly comparable to those observed in TOURMALINE-MM1 [12–17]. However,
global, long-term data in a large, varied and unselected patient population are lacking. Therefore, we performed a
pooled analysis of the INSIGHT MM observational study (NCT02761187) and the Czech Registry of Monoclonal
Gammopathies (RMG), referred to as ‘INSIGHT-RMG’ going forward, to evaluate the effectiveness and safety of
IRd in patients with RRMM in routine clinical practice.
Methods
Included studies & patients
This was a pooled analysis of data for RRMM patients who received IRd from INSIGHT MM (NCT02761187) [8]
and the Czech RMG [18]. INSIGHT MM is the largest global, prospective, observational study in MM to date,
which has enrolled 4311 adult patients with newly diagnosed MM or RRMM who have received one to three
prior therapies, from 15 countries worldwide. Longitudinal follow-up of patients is planned for an extended period
of time in an effort to track patterns of disease presentation, patient characteristics, treatment patterns, clinical
outcomes and safety, as well as the impact of the disease and its management on the patient’s quality of life
and healthcare resource utilization [8]. The Czech RMG includes clinical data on diagnosis, treatment, treatment
outcomes and survival for >7000 patients with MM. Data were analyzed for the study period from 1 July 2016 to
September 2019 for INSIGHT MM and from 1 May 2007 to 5 February 2020 for the Czech RMG.
For this analysis, adult patients with RRMM, with ≥1 prior therapy, who had been treated with IRd, were
identified. INSIGHT MM patients could have received IRd at any line of therapy after study entry. Patients from
the two registries who received a regimen with an ixazomib-lenalidomide backbone therapy as index regimen were
included in the analysis. INSIGHT MM patients required prospectively collected data on IRd therapy; patients
who signed the study informed consent from more than 3 months after starting IRd were excluded from the
analysis. RMG patients from 11 Czech centers who received IRd were included; patients who had incomplete or
missing data were excluded. Treatment within the context of a clinical trial was permitted for Czech RMG patients.
Data extraction & end points
Individual patient-level data on demographics, disease characteristics, treatment history (including therapies received
before and after IRd), effectiveness and safety for RRMM patients who had received IRd from INSIGHT-RMG
future science group 10.2217/fon-2020-1225
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were integrated and analyzed. Treatment effectiveness was evaluated by best response to therapy (defined as the
best response recorded at any timepoint), and through assessment of DOT, time-to-next treatment (TTNT), PFS
and overall survival (OS). DOT was defined as time from IRd initiation to discontinuation of therapy or death
from any cause. TTNT was defined as the interval from initiation of IRd to 1 day prior to the start of a new
line of therapy. PFS was defined as the time from IRd initiation to disease progression or death from any cause,
whichever came first; OS was defined as the time from IRd initiation to death from any cause. Response and PFS
were defined based on International Myeloma Working Group criteria, per the assessment of the treating physician
or local investigator [19]. Time to response was defined slightly differently in the INSIGHT MM study and the
Czech RMG database analysis, per individual protocols: in INSIGHT MM, it was defined as the time interval from
initiation of IRd therapy to initial achievement of best response; in the analysis of the Czech RMG, it was defined
as the time from initiation of IRd to first documented response of partial response (PR) or better (i.e. even if the
response improved during the IRd treatment, time to response was captured as the time to first response of PR or
better only). Safety was assessed by recording dose reductions and discontinuations of ixazomib or lenalidomide,
and the reasons for these events during the study period.
Statistical analysis
The time-to-event end points of DOT, PFS and OS were estimated using Kaplan–Meier methodology. TTNT
was estimated using a cumulative incidence (competing risk) method. Death was considered a competing risk in
TTNT analyses and was not censored.
Overall, analyses were primarily descriptive and no statistical comparisons between groups were made. Responses
were evaluated for each data set (INSIGHT MM and Czech RMG). Patient baseline characteristics and outcomes
(DOT, TTNT, PFS and OS) were analyzed for all patients and by line of IRd therapy in which IRd was received
(second, third, fourth and >fourth line). Analyses of PFS for patients who received IRd in second line versus
>second line and for patients who received IRd in second and third lines versus >third line, were also conducted.
Aggregated safety data per patient are reported. If treatment was modified or interrupted more than once, all
reasons for all actions were considered; therefore, patients could have more than one documented reason for taking
an action on a drug.
For all effectiveness and safety analyses, missing data were not included in the denominators for percentages.
The analyses were conducted using SAS R© v9.4. Data analysis was performed by Matyáš Kuhn, Jiř́ı Šilar and Lenka
Čápková (Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic), as well as the sponsor, and all authors
had access to the primary clinical trial data.
Results
Patients
At data cut-off, 263 patients from 13 countries who had received IRd had been included in the analyses, with 132
patients from INSIGHT MM and 131 from the Czech RMG (Supplementary Table 2). Countries from which
>20 patients were included were the Czech Republic (n = 131), the UK (n = 50) and the USA (n = 25). Patients had
received a median of two prior lines of treatment (range: 1 to 9). Overall, 44% (n = 115) of patients received IRd
in second line (INSIGHT MM, 35%, n = 46; Czech RMG, 53%, n = 69), 35% (n = 93) in third line (INSIGHT
MM, 44%, n = 58; Czech RMG, 27%, n = 35), 11% (n = 29) in fourth line (INSIGHT MM, 14%, n = 19; Czech
RMG, 8%, n = 10) and 10% (n = 26) in >fourth line (INSIGHT MM, 7%, n = 9; Czech RMG, 13%, n = 17).
Patient baseline characteristics and disease characteristics are summarized in Table 1. Median age of patients
at start of IRd therapy was 68 years (range: 40 to 87), with 15% of patients aged more than 75 years, and
56% were male. Patients were almost equally distributed across International Staging System (ISS) stages at
diagnosis. Most patients received IRd at an academic or university facility (86%), 14% of patients were treated
in community hospital or clinic and 4% (n = 5) of patients overall received IRd in the context of a clinical trial
(INSIGHT MM, n = 3; Czech RMG, n = 2). At the start of IRd therapy, the most common M-protein type was
immunoglobulin G (69%) and 21% of patients had extramedullary disease (extramedullary mass not related to
bone, bone-related extramedullary tumor mass, or both). All patients with extramedullary disease also had CRAB
criteria (hypercalcemia, renal insufficiency, anemia and bone lesions) present. A clinical relapse (defined as the
presence of extramedullary disease and/or CRAB criteria) occurred in 59% of patients and a biochemical relapse in
41% of patients. Overall, 7% of patients had high-risk cytogenetics recorded at any time before IRd treatment, 24%
10.2217/fon-2020-1225 Future Oncol. (Epub ahead of print) future science group
IRd for RRMM in routine clinical practice Research Article
Table 1. Patient demographics and disease characteristics, overall and by line of ixazomib-lenalidomide-dexamethasone
therapy.
Characteristic All (N = 263) Second line (n = 115) Third line (n = 93) Fourth line (n = 29) >Fourth line (n = 26)
Male, n (%) 146 (56) 59 (51) 48 (52) 23 (79) 16 (62)
Median age at start of IRd, years (range) 68 (40–87) 70 (41–84) 67 (40–87) 67 (45–79) 67 (52–81)
Age at start of IRd, n (%), years
– 50 18 (7) 9 (8) 7 (8) 2 (7) 0
– 50–65 90 (34) 32 (28) 35 (38) 11 (38) 12 (46)
– 66–75 115 (44) 52 (45) 36 (39) 15 (52) 12 (46)
– 75 40 (15) 22 (19) 15 (16) 1 (3) 2 (8)
ISS stage at diagnosis, n (%) n = 216 n = 105 n = 65 n = 21 n = 25
– I 73 (34) 32 (30) 24 (37) 6 (29) 11 (44)
– II 67 (31) 40 (38) 19 (29) 3 (14) 5 (20)
– III 76 (35) 33 (31) 22 (34) 12 (57) 9 (36)












IRd treatment facility, n (%)†
– Academic/university 225 (86) 102 (89) 79 (85) 23 (79) 21 (81)
– Community hospital/clinic 38 (14) 13 (11) 14 (15) 6 (21) 5 (19)












ECOG performance status at start of
IRd, n (%)
n = 216 n = 105 n = 71 n = 21 n = 19
– 0 63 (29) 24 (23) 26 (37) 9 (43) 4 (21)
– 1 123 (57) 60 (57) 39 (55) 11 (52) 13 (68)
– 2 27 (13) 18 (17) 6 (8) 1 (5) 2 (11)
– 3 3 (1) 3 (3) 0 0 0
M-protein type at start of IRd, n (%) n = 218 n = 101 n = 68 n = 23 n = 26
– IgG 150 (69) 62 (61) 49 (72) 17 (74) 22 (85)
– IgA 43 (20) 26 (26) 12 (18) 3 (13) 2 (8)
– Light chain 19 (9) 11 (11) 4 (6) 2 (9) 2 (8)
– Other 6 (3) 2 (2) 3 (4) 1 (4) 0
Cytogenetic features prior to/at start of
IRd, n (%)¶
– High-risk cytogenetics abnormalities 19 (7) 11 (10) 4 (4) 1 (3) 3 (12)
– Standard-risk cytogenetics
abnormalities
63 (24) 32 (28) 20 (22) 6 (21) 5 (19)
– Data not available 181 (69) 72 (63) 69 (74) 22 (76) 18 (69)
Type of relapse, n (%)§
– Clinical relapse 154 (59) 77 (67) 48 (52) 11 (38) 18 (69)
– Biochemical relapse 109 (41) 38 (33) 45 (48) 18 (62) 8 (31)












†71% and 100% of INSIGHT MM and Czech RMG patients, respectively, were treated at academic/university facilities; 29% and 0% of INSIGHT MM and RMG patients, respectively,
were treated at community hospital/clinic facilities.
‡Extramedullary disease was considered any of the following options: extramedullary mass not related to bone, bone-related extramedullary tumor mass or both.
§Clinical relapse was recorded for patients with CRAB criteria, extramedullary disease, or both, at the time of starting IRd therapy; biochemical relapse was recorded for patients with
none of these parameters.
¶High-risk cytogenetic abnormalities were detected by fluorescence in situ hybridization (FISH) and were defined as del(17p), t(4;14), t(14;16) detected any time before the start of IRd
treatment. For INSIGHT MM, cytogenetic results were assessed at relapse whereas, for RMG, they could be evaluated at any time.
#Refractory was defined as progression while on or within 60 days of discontinuing a PI (bortezomib or carfilzomib)-containing or lenalidomide-containing regimen.
CRAB: Hypercalcemia, renal insufficiency, anemia, bone lesions; ECOG: Eastern Cooperative Oncology Group; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IRd: Ixazomib-lenalidomide-
dexamethasone; ISS: International Staging System; PI: Proteasome inhibitor; RMG: Registry of Monoclonal Gammopathies.
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Table 1. Patient demographics and disease characteristics, overall and by line of ixazomib-lenalidomide-dexamethasone
therapy (cont.).
Characteristic All (N = 263) Second line (n = 115) Third line (n = 93) Fourth line (n = 29) >Fourth line (n = 26)
Therapies received in any previous line
before IRd, n (%)
– Bortezomib 238 (90) 100 (87) 86 (92) 27 (93) 25 (96)
– Stem-cell transplantation 145 (55) 47 (41) 56 (60) 20 (69) 22 (85)
– Allogeneic stem-cell transplantation 2 (1) 0 (0) 1 (1) 0 (0) 1 (4)
– Thalidomide 121 (46) 25 (22) 57 (61) 20 (69) 19 (73)
– Lenalidomide 71 (27) 14 (12) 21 (23) 17 (59) 19 (73)
– Carfilzomib 24 (9) 6 (5) 8 (9) 3 (10) 7 (27)
– Daratumumab 22 (8) 4 (3) 5 (5) 5 (17) 8 (31)
– Pomalidomide 5 (2) 0 (0) 0 (0) 0 (0) 5 (19)
Refractory to prior therapy, n (%)#
– PI 27 (10) 8 (7) 9 (10) 3 (10) 7 (27)
– Lenalidomide 19 (7) 2 (2) 5 (5) 6 (21) 6 (23)
†71% and 100% of INSIGHT MM and Czech RMG patients, respectively, were treated at academic/university facilities; 29% and 0% of INSIGHT MM and RMG patients, respectively,
were treated at community hospital/clinic facilities.
‡Extramedullary disease was considered any of the following options: extramedullary mass not related to bone, bone-related extramedullary tumor mass or both.
§Clinical relapse was recorded for patients with CRAB criteria, extramedullary disease, or both, at the time of starting IRd therapy; biochemical relapse was recorded for patients with
none of these parameters.
¶High-risk cytogenetic abnormalities were detected by fluorescence in situ hybridization (FISH) and were defined as del(17p), t(4;14), t(14;16) detected any time before the start of IRd
treatment. For INSIGHT MM, cytogenetic results were assessed at relapse whereas, for RMG, they could be evaluated at any time.
#Refractory was defined as progression while on or within 60 days of discontinuing a PI (bortezomib or carfilzomib)-containing or lenalidomide-containing regimen.
CRAB: Hypercalcemia, renal insufficiency, anemia, bone lesions; ECOG: Eastern Cooperative Oncology Group; IgA: Immunoglobulin A; IgG: Immunoglobulin G; IRd: Ixazomib-lenalidomide-
dexamethasone; ISS: International Staging System; PI: Proteasome inhibitor; RMG: Registry of Monoclonal Gammopathies.
had standard-risk cytogenetics and data were missing for the remaining 69%. Median time from initial diagnosis
to start of IRd was 35.8 (range: 3.0–387.4) months.
Among all patients, 86% (n = 226) reported relapse or progression as the reason for initiation of IRd therapy
(85% [n = 98] in second line, 83% [n = 77] in third line, 90% [n = 26] in fourth line and 96% [n = 25] in
>fourth line); 10% (n = 25) of patients reported insufficient response as a reason for starting IRd and 3% (n = 9)
provided another reason (Supplementary Figure 1). Clinical symptoms (CRAB criteria) reported at relapse prior
to IRd initiation are presented in Supplementary Figure 2: 40% (n = 106) of patients reported bone lesions, 17%
(n = 45) reported anemia, 3% (n = 8) reported renal insufficiency and 2% (n = 6) reported hypercalcemia.
Treatments received before IRd in any previous line included bortezomib (90%), stem cell transplantation
(55%; <1% allogeneic), thalidomide (46%), lenalidomide (27%), carfilzomib (9%), daratumumab (8%) and
pomalidomide (2%) (Table 1). 10% of patients were refractory to prior proteasome inhibitor-containing therapy
(bortezomib or carfilzomib) and 7% were refractory to prior lenalidomide-based regimens.
Response & outcomes with IRd
Data on best response to IRd were available for 186 patients (INSIGHT MM, n = 71; Czech RMG, n = 115). For
all patients, the combined ORR was 73% (INSIGHT MM, 73%, n = 52; Czech RMG, 73%, n = 84), including
37% of patients who achieved ≥VGPR (INSIGHT MM, 35%, n = 25; Czech RMG, 38%, n = 44) (Figure 1).
Median time to best response was 3.4 months (range: 0.7–15.2) among INSIGHT MM patients. For Czech RMG
patients, median time to first response of PR or better was 1.2 months (range: 0.2–16.9).
Median duration of follow-up for all patients was 14.8 months. At data cut-off, 159 patients (61%) had discon-
tinued IRd; reasons for discontinuation were relapse/progression (43%, n = 68), completed regimen/treatment
response (14%, n = 22), resistance/insufficient response (12%, n = 19), death (11%, n = 17), AE (7%, n = 11),
patient preference (3%, n = 4), other (6%, n = 9) and unknown (6%, n = 9). Median DOT was 11.8 months
(Figure 2A) and was longer in patients receiving IRd in second or third line (12.8, 13.0 months) versus fourth or
>fourth line (8.5, 5.2 months) of therapy (Supplementary Figure 3A). Among all patients, median TTNT was
33.0 months (Figure 2B) and was longer for patients receiving IRd in earlier lines (35.2 and 27.7 months in second
and third line, respectively) versus later lines of therapy (23.3 months and not reached in fourth and >fourth line,
respectively) (Supplementary Figure 3B). The treatment-free interval according to reason for discontinuation of
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Figure 1. Best response (INSIGHT multiple
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multiple myeloma) or first (Czech registry
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ixazomib-lenalidomide-dexamethasone.
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IRd is presented in Supplementary Table 3. A total of 119 (45%) patients had experienced PFS events and 75 (29%)
had had OS events. Overall median PFS was 21.2 months (Figure 2C); and 26.0, 23.8, 13.6 and 6.7 months in
patients receiving IRd in second third, fourth and >fourth line, respectively (Supplementary Figure 3C). Median
PFS was significantly longer in second versus >second line (HR: 0.66; 95% CI: 0.45–0.95; p = 0.026) and also for
patients who received IRd in second and third lines versus >third line (HR: 0.44; 95% CI: 0.29–0.66; p < 0.001).
Median OS, for all patients and for those receiving IRd in second, third and fourth line, was not reached; median
OS in >fourth line was 9.8 months (Figure 2D & Supplementary Figure 3D).
Subsequent treatment
Ninety-one patients had complete records of subsequent treatment immediately after IRd therapy. Among these
patients, 26% (n = 24) received subsequent daratumumab, 24% (n = 22) received pomalidomide, 20% (n = 18)
received bortezomib, 19% (n = 17) received lenalidomide, 14% (n = 13) received carfilzomib, 9% (n = 8) received
thalidomide, 3% (n = 3) underwent stem cell transplantation and 12% (n = 11) received other therapies.
Safety
Ixazomib and lenalidomide dose reductions were required in 17% (n = 44) and 36% (n = 95) of patients treated
with IRd, respectively; 10% (n = 27) of patients required ixazomib dose reductions due to documented adverse
events (AEs), with the most common AEs leading to these events being diarrhea, neutropenia, thrombocytopenia
and neuropathy (2% each) (Supplementary Table 4). Lenalidomide dose reductions due to documented AEs were
required for 23% (n = 60) of patients; the most common AEs leading to these events were neutropenia (7%),
thrombocytopenia (5%), fatigue and diarrhea (3% each) (Supplementary Table 4). Ixazomib and lenalidomide
discontinuations, including temporary interruptions and dose delays, were reported in 50% of patients (n = 131 and
130, respectively); 32% (n = 83) required discontinuation of ixazomib due to documented AEs, most frequently
due to infection (19%), neutropenia or thrombocytopenia (6% each) (Supplementary Table 4). Lenalidomide
discontinuations due to documented AEs were required for 30% (n = 78) of patients and the most frequent AEs
leading to this action were infection (20%), neutropenia (6%) and thrombocytopenia (5%) (Supplementary Table
4). Patients may have had multiple reasons for discontinuation documented and those with a dose reduction may
have also subsequently discontinued treatment.
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Figure 2. Time-to-event end points with ixazomib-lenalidomide-dexamethasone for the overall patient population
(N = 263). (A) Duration of therapy, (B) time-to-next treatment, (C) progression-free survival and (D) overall survival.
DOT, PFS and OS were analyzed using Kaplan–Meier methodology. TTNT was determined by cumulative incidence
analysis.
DOT: Duration of therapy; NR: Not reached; OS: Overall survival; PFS: Progression-free survival; TTNT: Time-to-next
treatment.
Discussion
Observational studies are important for establishing the real-world effectiveness of medications and are particularly
relevant in MM, where treatment outcomes in routine clinical practice often fail to match those reported in
Phase III trials [1]. This pooled analysis of INSIGHT-RMG demonstrated that the effectiveness of IRd treatment
in routine clinical practice (ORR: 73%; median PFS: 21.2 months) was similar to that reported in the regis-
trational TOURMALINE-MM1 trial (ORR: 78%; median PFS: 20.6 months) [11], as shown in Supplementary
Table 1. This comparable level of effectiveness was observed despite the pooled INSIGHT-RMG population hav-
ing more advanced disease (ISS stage II/III: INSIGHT-RMG, 31%/35%; TOURMALINE-MM1, 25%/12%),
a worse performance status (Eastern Cooperative Oncology Group performance status 2/3: INSIGHT-RMG,
13%/1%; TOURMALINE-MM1, 5%/0%), a greater number of prior lines of therapies (1/2/3/≥4 prior thera-
pies: INSIGHT-RMG, 44%/35%/11%/10%; TOURMALINE-MM1, 62%/27%/11%/0%) and greater prior
exposure to proteasome inhibitors and immunomodulatory drugs (including lenalidomide) than patients receiving
IRd in the TOURMALINE-MM1 study (Supplementary Table 1) [11]. In addition, patients with comorbidities
were not excluded from the INSIGHT MM and Czech RMG registries, whereas in TOURMALINE-MM1,
patients were excluded if investigators deemed them inappropriate for study entry based on the presence of a
comorbid systemic illness or other severe concurrent disease [11]. Patients who were refractory to prior bortezomib
or lenalidomide therapy were also excluded from TOURMALINE-MM1, whereas in INSIGHT-RMG, 10 and
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7% of patients were refractory to bortezomib and lenalidomide, respectively. Age, sex, time since diagnosis and
rates of prior transplantation were, however, similar between the two populations (Supplementary Table 1).
Our data support growing evidence that outcomes in RRMM patients treated with IRd in routine clinical
practice are in line with those reported in TOURMALINE-MM1 [11]. This seemingly narrow gap between efficacy
and effectiveness is encouraging, particularly in the context of results from a network meta-analysis of treatment
outcomes in RRMM, in which IRd was ranked as one of the most effective treatment options evaluated [20]. Other
smaller registry studies and analyses in the nonclinical trial setting of ixazomib in RRMM patients have reported
generally similar ORRs (range: 66–88%) and PFS outcomes (range of medians: 11.4–27.6 months) to those reported
here and in TOURMALINE-MM1 [11–17]. Analyses of electronic medical records (EMR)/claims-based data showed
median PFS values of 11.1 and 13.5 months for ixazomib-based regimens [2,21]. Comparative retrospective analyses
of real-world outcomes in US RRMM patients receiving ixazomib-, carfilzomib-, or bortezomib-based therapy,
using the Optum EMR database, indicated a gap between clinical trial efficacy and real-world effectiveness for
all three proteasome inhibitor (PI)-Rd combinations, this being most pronounced for carfilzomib-Rd (KRd) [2].
Prolonged PI-based treatment appeared feasible with ixazomib (median DOT of 12.3 months) compared with the
parenteral PIs (median DOT of 10.0 months with bortezomib-Rd [VRd], 7.2 months with KRd) [2]. After adjusting
for covariates, TTNT was similar with IRd, VRd and KRd in the overall patient populations, but was significantly
shorter with KRd versus IRd or VRd in intermediate or frail patients, who are typically underrepresented in clinical
trials and was numerically longer with KRd among fit patients [2]. In another similar study, while unadjusted
median TTNT was longer for ixazomib-based triplet regimens (11.1 months) compared with bortezomib-based
triplets (9.8 months), the difference was not significant after adjustment for patient and disease characteristics [21].
Collectively, these data indicate real-world effectiveness with PI-Rd triplet regimens in the patient populations for
which they are selected. Similarly to ixazomib, recent registry/observational studies as well as EMR/claims-based
analyses of patients treated in the non-clinical trial setting also suggest similar median PFS/TTNT values with
bortezomib-based [2,21–27] and carfilzomib-based [2,21,24,25,27–32] regimens to those seen in Phase III studies [33–35].
Clinically meaningful activity was demonstrated for IRd treatment across all lines of therapy, and median PFS
was significantly longer in patients who received IRd in earlier lines of therapy compared with those who received
the regimen in later lines. However, it should be noted that for all time-to-event analyses the number of patients
receiving IRd in fourth and >fourth line was small. Real-world data reports of IRd in RRMM [14–17,36,37], also
support the trend seen in the present study for prolonged PFS in patients who received IRd earlier in their treatment
course. This observation is expected, and is consistent with previous studies showing that PFS, duration of response
and OS for RRMM patients decrease with successive lines of treatment [25,36–38]. This is in contrast with results
from TOURMALINE-MM1, showing that PFS benefit with IRd versus Rd appeared to be more pronounced in
patients with two or three prior lines of therapy as compared with those with just one prior therapy [39]. This
highlights the fact that outcomes observed in routine clinical practice may not always match those observed in
clinical trials, underscoring the importance of real-world data to improve our understanding of the true therapeutic
benefit of anti-myeloma regimens in routine clinical practice. Further analysis of these specific patient populations
is warranted, to account for any bias in the selection of treatment regimens across lines of therapy.
Our INSIGHT-RMG analysis suggests that IRd is well tolerated by patients in routine clinical practice, with no
new safety signals observed during the study period. Notably, rates of dose reductions due to AEs for ixazomib and
lenalidomide were low (10 and 23%, respectively), while rates of drug discontinuations due to AEs were similar for
the two drugs (32 and 30%, respectively). The most common AEs leading to dose reductions or discontinuations
were hematologic and gastrointestinal events, infections and fatigue, which is in line with the safety profile reported
in the IRd arm of the TOURMALINE-MM1 study [11]. Safety findings from this pooled analysis are also comparable
to those reported in other real-world studies of ixazomib-based therapy [12–17]. In addition to offering a tolerable
treatment option, the all-oral IRd regimen could also represent a convenient treatment approach for patients who
may find it difficult to access infusion centers or who do not want to travel to a hospital or clinical setting to receive
treatment, which is critically important during the current COVID-19 pandemic. Therefore, IRd therapy offers
the potential for improved medication adherence compared with regimens which include a parenteral component.
Additionally, the administration of an all-oral treatment regimen has been associated with increased patient-reported
satisfaction with treatment convenience [40].
As with all real-world, observational studies, there are limitations associated with the conclusions drawn from
the data. While providing an important indication of effectiveness and safety, the outcomes reported in this study
should be interpreted with caution due to the limited maturity of the data, particularly in later lines where the
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patient numbers are small. Secondly, there was a high number of patients with missing response data, which is
likely a consequence of several factors: the quarterly data collection procedures employed in INSIGHT MM, which
can result in a long period of time between the relevant laboratory analysis and the point at which results are
recorded in the case report forms; the fact that documentation of depth of response within patients’ progress notes
is not routine; the lack of a standard process for the documentation of the interpretation of response assessments in
patients’ progress notes, which makes it difficult for the study coordinators to accurately interpret and record this
information; and the continuous enrolment/registration of new patients, meaning that many patients will not yet
have sufficient follow-up for a response to be documented. Thirdly, it should be emphasized that many patients
included in this analysis (including all patients in the Czech RMG) were treated at academic centers, as these were
often the only sites where IRd was available; therefore, the results may not be representative of the community
practice setting. It is possible that inclusion of more patients from community settings, who may be older and
more frail, and fewer patients from academic centers, akin to those centers used in clinical trials, may impact the
real-world outcomes seen with IRd therapy; this will require further investigation. Fourthly, missing or inconclusive
cytogenetic data prohibited an analysis of the effectiveness of IRd according to cytogenetic features. A subgroup
analysis of the TOURMALINE-MM1 study has previously shown that IRd improves the prognosis for patients
with high-risk cytogenetics, with PFS similar to that in patients with standard-risk cytogenetics [11]. Lastly, as in
most observational studies, potential bias may be present in the data due to unobserved treatment selection biases
associated with any non-randomized study design.
In summary, the findings from this pooled analysis of global observational data from INSIGHT MM and the
Czech RMG suggest that the effectiveness of IRd in routine clinical practice may be comparable to the efficacy
reported in the registrational, Phase III TOURMALINE-MM1 trial [11]. These real-world data suggest that IRd
provides a greater benefit to patients with RRMM when given in earlier (second or third) versus later lines of
therapy. The data also suggest that IRd is well tolerated by patients when used in routine clinical practice, including
older patients and those with advanced disease and/or multiple comorbidities, with no new safety signals.
Future perspective
MM is a highly heterogeneous disease; growing evidence suggests that individualized treatment provides the best
chance for prolonged remission. In addition to the ongoing study of current agents, the development of therapeutics
for MM with novel mechanisms of action continues at a rapid pace and new treatment combinations with existing
agents are continuously being explored. New therapies focus on improving the ability of the immune system to fight
cancer and are broadly referred to as immunotherapy or cellular therapies. How best to combine or sequence these
agents with existing effective therapies such as proteasome inhibitors will be explored. In addition, all-oral treatment
combinations will continue to be important, potentially offering improved medication adherence compared with
parenterally administered therapies. This is particularly relevant for elderly and frail patients, and for those who are
unable to, or are unwilling to make frequent trips to receive medication.
Collection of real-world data with the use of well-managed registries is integral to our understanding of how
approved regimens perform outside of randomized controlled trials. The prospective collection of real-world data
for these new therapeutic modalities and combinations, alongside pivotal randomized trial data, will lead to a more
complete picture of effectiveness and help to develop confidence in the use of these treatments, which in turn
should lead to better outcomes for patients with MM.
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maceutical Company Limited. R Hájek: consultancy, honoraria, membership on an entity’s board of directors or advisory com-
mittees, and research funding for Janssen, Amgen, Celgene and Bristol-Myers Squibb; consultancy for AbbVie; consultancy and
research funding for Novartis; consultancy, honoraria and membership on an entity’s board of directors or advisory committees
for PharmaMar; consultancy, consultant or advisory relationship, honoraria, membership on an entity’s board of directors or ad-
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Summary points
• Clinical outcomes in multiple myeloma often differ in routine clinical practice compared with clinical trial data.
• We performed a pooled analysis of the global, prospective, observational INSIGHT MM study and the Czech
Registry of Monoclonal Gammopathies (RMG) to evaluate the effectiveness and safety of
ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory MM in routine clinical practice.
• Patient-level data on demographics, disease characteristics, treatment history, effectiveness and safety from both
registries were integrated and analyzed.
• At data cut-off, 263 patients (132 INSIGHT MM, 131 Czech RMG) from 13 countries were included.
• Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months.
• Among 186 patients with best response data available, overall response rate (ORR) was 73%; median
progression-free survival (PFS) and time-to-next therapy were 21.2 (95% confidence interval [CI]: 15.2–25.9) and
33.0 (95% CI: 26.2–47.4) months, respectively.
• Ixazomib and lenalidomide dose reductions were required in 17 and 36% of patients, respectively (10 and 23%
due to adverse events [AEs], most commonly hematologic and gastrointestinal AEs, and fatigue).
• A total of 32 and 30% of patients discontinued ixazomib and lenalidomide, respectively, due to AEs, most
frequently, infection and hematologic events.
• The effectiveness of IRd in routine clinical practice is comparable to the efficacy of IRd reported in the Phase III
TOURMALINE-MM1 trial (ORR: 78%; median PFS: 20.6 months).
• IRd is well tolerated, with no new safety signals, and rates of dose reductions and discontinuations due to AEs
similar to those reported in TOURMALINE-MM1.
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